The US Food and Drug Administration (FDA) has accepted Bayer‘s biologics licence application (BLA) filing for BAY94-9027 to treat haemophilia A in adults and adolescents 12 years of age and above.

Haemophilia A is the most common type of haemophilia, in which blood clotting is affected either due to a lack or defect of coagulation Factor VIII (FVIII), a protein required to form blood clots.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Bayer’s investigational agent BAY94-9027 is an extended half-life site-specifically PEGylated recombinant human Factor VIII compound that is used for the treatment of the largely inherited disease.

Bayer Medical Affairs Americas senior vice-president and head Dr Dario Mirski said: “The filing acceptance for BAY94-9027 by the FDA represents a milestone to Bayer in its commitment to seeking potential treatments to address the unmet needs of people living with haemophilia A.”

“The filing acceptance for BAY94-9027 by the FDA represents a milestone to Bayer in its commitment to seeking potential treatments to address the unmet needs of people living with haemophilia A.”

The BLA submission is based on the results obtained from the pivotal multicentre, multinational, partially randomised, open-label Phase II / III PROTECT VIII clinical trial.

With four treatment arms, the trial was conducted to study the safety and efficacy of BAY94-9027 in previously treated adults and adolescents with severe haemophilia A.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In three of the prophylactic treatment arms, efficacy and safety of the therapy was evaluated when used once every seven days, once every five days or twice per week.

The therapy is developed to potentially prolong the FVIII activity in blood while preserving coagulation activity using site-specific PEGylation technology, where a Polyethylene glycol (PEG) molecule is consistently attached to the factor VIII protein at a specific site.

An increased half-life recombinant factor VIII treatment may facilitate reduced frequency of infusions for patients affected with haemophilia A.